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Abstract
Curcumin, a natural diphenolic compound derived from turmeric Curcuma longa, has proven to be
a modulator of intracellular signaling pathways that control cancer cell growth, inflammation,
invasion, apoptosis and cell death, revealing its anticancer potential. In this review, we focus on
the design and development of nanoparticles, self-assemblies, nanogels, liposomes and complex
fabrication for sustained and efficient curcumin delivery. We also discuss the anticancer
applications and clinical benefits of nanocurcumin formulations. Only a few novel multifunctional
and composite nanosystem strategies offer simultaneous therapy as well as imaging
characteristics. We also summarize the challenges to developing curcumin delivery platforms and
up-to-date solutions for improving curcumin bioavailability and anticancer potential for therapy.
Cancer continues to be the second leading cause of death in the USA. Current
chemotherapeutic agents, such as alkylating agents, mustards, anti-metabolites, spindle
poisons, and DNA binders and cutters, target a specific pathway, which ultimately shrinks
tumor size but often fails to eradicate tumors or prevent their recurrence. Repeated treatment
with these agents eventually results in tumors that become resistant to the chemotherapies.
Therefore, it is crucial to identify ‘natural products’ that have growth inhibitory and
apoptosis induction properties on human cancer cells and that target multiple cellular
signaling pathways without resulting in toxicity issues in normal cells. Curcumin, a
diphenolic compound extracted from the rhizome of turmeric (Curcuma longa), is a
prominent candidate for treating anti-inflammatory, cystic fibrosis, Alzheimer’s and malarial
diseases in addition to cancer [1].
A comprehensive review of the literature characterized curcumin as an excellent molecule
among many naturally occurring compounds for cancer therapeutics [2]. Pleiotropic
properties of the curcumin molecule enable it to target the genome (DNA), messengers
(RNA) and enzymes (proteins) within cells, actions that can be sequential or simultaneous.
Specifically, unlike other chemotherapeutic agents, curcumin exhibits pleiotropic properties
that involve the modulation of nuclear factor-kappaB (NF-κB), transcription factor activator
protein-1 (AP-1), mitogen-activated protein kinase (MAPK), tumor protein 53 (p53), nuclear
β-catenin signaling, and serine/threonine protein kinase (AKT) signaling pathways [3].
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Curcumin has been shown to suppress the expression of epidermal growth receptor and
estrogen receptors, which are cancer-associated growth factors [4]. Some proof-of-concept
studies have demonstrated that curcumin efficiently sensitizes tumor cells to first-line
chemotherapies and radiation [5–7]. The development of multidrug resistance (MDR) in
cancer therapeutics results in a minimal response to conventional cytotoxic agents and
targeted biological therapies [8–10]. This occurs as a result of the overexpression of ATP-
binding cassette transporters, which act as drug–efflux pumps involved in the aggressive
removal of drug molecules from the cells, which therefore reduces the intracellular levels of
these therapeutic molecules. This phenomenon can be overcome by curcumin treatment,
which downregulates P-glycoprotein (P-gp), breast cancer resistance protein (ABCG2) and
multidrug resistance protein (MRP-1) expression [11]. Owing to its valuable properties,
almost 100 pharmaceutical and chemical companies are producing various curcumin
products in the form of tablets, capsules, coloring agents, creams, dairy, drinks, extracts,
gels, nasal sprays, and so on. for daily and medical needs [12]. Various clinical trials are
underway or have been completed to judge the efficacy of curcumin as a therapeutic
molecule in medicine (http://clinicaltrials.gov/ct2/results?term=curcumin).
A major limiting factor of curcumin is its low solubility in water (i.e. 0.0004 mg/ml at pH
7.3) and soluble curcumin molecules are extremely sensitive at physiological pH [13–17].
Many preclinical and clinical studies in mice, rats and humans revealed a low bioavailability
of curcumin [2,18]. Although 10 or 12 g/ml of curcumin administered orally in humans
showed curcumin levels in serum to be approximately 50 ng/ml, this resulted in a minimum
availability of curcumin in the blood circulation to achieve its therapeutic effects [19].
Proven explorations suggest that improved curcumin properties; targeted delivery, tissue
distribution and bioavailability in tumors can be efficiently achieved in the presence of an
adjuvant, piperine [20,21].
A simple way of solving the limiting factors of curcumin is to improve its bioavailability,
protect it from degradation and metabolism, and increase its targeting capacity toward
cancer tumor(s). Various types of nanoparticle (NPs), such as polymer NPs, polymeric
micelles, liposome/phospholipid, nano-/microemulsions, nanogels, solid lipid NPs, polymer
conjugates, self-assemblies, and so on, are suitable for the delivery of an active form of
curcumin to tumors (Figure 1a) [22]. Research efforts during the past 8–10 years have been
devoted to this direction. A year-by-year diagram describing its increasing use by the
medical community is shown in Figure 1b. Our group has developed a series of curcumin or
anticancer nanoformulations for effective anticancer, hyperthermia and imaging applications
in cancer therapy (Figure 1c) [7,23–28]; a short description on available curcumin
nanoformulations is provided in Table 1. The improved solubility, bioavailability and
pharmacokinetic properties of curcumin through various micro- and/or nanoformulations
have been reviewed systematically elsewhere [29,30]. Therefore, the focus of this review is
to discuss the design and development of NPs, self-assemblies, nanogels, liposome and
complex fabrication, and their important contributions to cancer therapeutics.
Curcumin nanocrystals and conjugates
Nano drug-crystals have a greater dissolution rate owing to a larger specific surface area
(Figure 2a). Development of successful nanocrystal formulation by any of these bottom-up
approaches depends on the stabilization process. Curcumin crystal formation is a time-
dependant process, in that it takes 90 min in a solution of alcohol and water [31]. After 90
min, curcumin crystals start to aggregate and form as a precipitate (Figure 2b). The
aggregation of surfactant molecules, including sodium dodecyl sulfate,
cetyltrimethylammonium bromide, Tween 80, Triton X-100 and pluronic polymers, form
micelles at a critical micelle concentration and can provide the required influence to stabilize
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curcumin molecules [32]. However, cationic micelles provide greater stability to curcumin
even at elevated pH and are preferred for their medicinal implications. Similarly, plasma
proteins have also been recognized as carriers for curcumin because of their ability to
stabilize curcumin molecules [33]. High-pressure homogenization (HPH) is a suitable
method for reducing bulk curcumin into NPs. The optimized condition for producing
curcumin crystals, as defined by increased dispersions, is at a temperature of 2°C and with
ten cycles of HPH with an applied pressure of 150 MPa [34]. Stable self-emulsifying liquid
formulations of curcumin with particles size of approximately 30 nm and approximately
99% curcumin loading have successfully been developed [35]. These formulations have a
10–14-fold greater absorption rate in male Wistar-strain rats given an oral treatment of 50
mg/kg of curcumin, compared with the same oral dose of free curcumin. D-α tocopheryl
polyethylene glycol 1000 succinate (TPGS) stabilized curcumin nanosuspension (CUR-NS)
crystal formulation has been evaluated for the pharmacokinetics and biodistribution of
curcumin after intravenous administration in rabbits and mice [36]. The area under the
plasma concentration (AUC; 0–∞) of CUR-NS (700.43±281.53 µg/ml, min) was 3.8-fold
greater than for a curcumin solution (145.4 ±9.29 µg/ml, min). The mean residence time was
11.2-fold longer with CUR-NS compared with a curcumin solution (194.57±32.18 min vs
15.88±3.56 min).
Polymer–drug conjugates are considered to be alternative therapeutics from the nanoscale
family. Two phenolic rings and active methylene groups are potential sites to conjugate any
biomacromolecules onto curcumin. Kumar et al. [37] designed nucleoside–curcumin
bioconjugates to obtain high levels of glucuronide and sulfate curcumin conjugates in
healthy human volunteers [38]. A recent patent technology based on a luteinizing hormone-
releasing hormone (LHRH)–curcumin conjugate synthesized by fluorenylmethoxycarbonyl
(Fmoc) solid phase has exhibited an improved antitumor effect in xenograft models of
pancreatic cancer [39]. Fmoc is a base label protecting group for LHRH or amine groups.
Mono- and diester bioconjugates of curcumin were prepared by solution phase synthesis
using urethane chemistry [40]. Methyl jasmonate and salicylic acid in cell culture media
enhanced the glucoside formation with curcumin (curcumin-4′,4′-O-beta-D-digentiobioside)
and showed higher solubility of curcumin (0.65 mmol/ml) [41]. Similarly, monoglutathionyl
curcumin conjugates can be achieved in biological systems when catalyzed in the presence
of human glutathione S-transferase [42]. Improved bioavailability and biological effects of
these curcumin conjugates were achieved as a result of excretion to the intestinal lumen.
Panday et al. [43] proposed novel polyethylene glycosylated (PEGylated) curcumin analogs
for potent nuclear factor erythroid-2 related factor 2 (Nrf2) activators, which regulate the
antioxidant defense system and act as modifiers for inflammatory diseases. These analogs
improved curcumin solubility from 0.6 × 10−6 to 0.98 × 10−6 g/ml. PEGylated curcumin
conjugates had a key role in growth inhibitory effects on a panel of human pancreatic cancer
cell lines [44]. The improved effects were achieved by greater suppression of Jun activation
domain-binding protein-1 (Jab1) activity by curcumin conjugates. This was confirmed by a
significant elevation of the protein levels of p27, Smad2, Smad4 and reduction of c-Jun by 5
µM conjugate. Emerging products of PEG–curcumin (PEG–CUR) nanoconjugates are
useful for obtaining a higher cytotoxicity in cancer cells [45]. The synergist activity is
dependent on the type of linker chain terminal functionality and molecular weight. A
cationic poly(vinyl pyrrolidone)–curcumin (PVP–CUR) conjugate formulation with stable
particle size and ζ potential with a pH range of 3–9 has been judged by MTT assay to be
more potent in L929 fibroblast cells over free curcumin [46].
Polycatocol–curcumin conjugates were synthesized by condensation polymerization of
curcumin and anhydrides [47]. An optimized polycatocol-curcumin conjugate (PCurc 8) is
highly cytotoxic to SKOV-3, OVCAR-3 ovarian cancers, and MCF-7 breast cancer cell lines
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(Figure 3a). These conjugates were taken up efficiently by cancer cells, hydrolyzed and
released in an active form of curcumin in lysosomes (Figure 3b). The arrest of cancer cell
growth was found in G(0)/G(1) phase and induced apoptosis through the caspase-3
dependent pathway (Figure 3c). A 68% decrease in tumor growth was observed with
intravenous injection of PCurc 8 in the SKOV-3 intraperitoneal tumor xenograft mouse
model compared with the control group [47]. Polyamine conjugates of curcumin analogs
were efficiently transported to mitochondria by intracellular uptake [48]. A direct
conjugation of curcumin molecules to carboxylic acid groups of a hyaluronic acid (HA)
polymer was performed to obtain nanosize micelle in aqueous solution through hydrophobic
interactions [49]. The equivalent of approximately 13 µg of curcumin in conjugate was able
to kill 80% of the L929 cells, indicating its potential in therapeutics. HA–curcumin
conjugates can be specifically targeted to cell-specific surface markers, such as CD44.
Curcumin emulsions, liposome and phospholipid formulations
Microemulsions are isotropic nanostructural, stable solutions comprising surfactant(s), oil
and water. Curcumin-based microemulsions are expected to improve curcumin delivery via
local and transdermal routes for scleroderma, psoriasis and skin cancer. Eucalyptol-based
curcumin microemulsions have very high permeability and flux with moderate solubility of
curcumin compared with many oleic acid- and esteem oil-based microemulsions [50]. The
enhanced penetration capacity of this applied curcumin microemulsion formulation, as well
as its effect on the cellular structure of skin, have been observed. Furthermore, a new
microemulsion (approximately 10 nm) composition of limonene, polysorbate 80, ethanol
and water promotes curcumin presence in skin (9.29–29.99 µg in an area of 0.785 cm2) [51].
Myristic, palmitic, stearic and behenic acids (i.e., fatty acids; FA)-based solid lipid NPs
were prepared by a coacervation technique in the presence of polymeric non-ionic
surfactants [52]. This method initially loaded up to 28–81% with a 500-nm particle size.
After hydrolysis, this diameter size reduced to 300 nm. A stable self-microemulsifying drug
delivery system (SMEDDS) comprising 20% ethanol, 60% Cremophor RH40® and 20%
isopropyl myristate was able to encapsulate 50 mg/ml of curcumin and to release it
completely in 10 min [53].
Curcumin microemulsions prepared in the presence of ethyl oleate and isopropyl myristate
result in homogeneous, yellow, transparent solutions, whereas soybean oil and peppermint
oil are turbid in nature [54]. Highly smooth surface gelatin microspheres with 75.5%
curcumin encapsulation efficiency were formulated by the emulsion crosslinking method
suitable for lung targeting [55]. These spheres are 5–30 µm in diameter, with 50% curcumin
release within 22 h for immediate therapeutic effects. Co-administration of curcumin and
paclitaxel nanoemulsion formulations are capable of overcoming multidrug resistance in
SKOV3 (TR) human ovarian adenocarcinoma cells by inhibiting NF-κB activity,
downregulating P-gp and promoting apoptotic responses [56]. Additionally, curcumin
nanoemulsion increases the bioavailability of paclitaxel up to 5.2-fold, and there is a 3.2-
fold increase in its accumulation at the tumor site in an oral administration to SKOV3
tumor-bearing xenograft mice models. This resulted from downregulation of intestinal P-gp
and cytochrome P450 3A2 (CYP3A2) protein levels [57].
Liposomes comprise artificial phospholipid vesicles, considered to be biologically safe,
biocompatible and protect drugs from external stimuli. It has been known that an extended
absorption capacity of curcumin can be attained by dissolving, mixing or complexing it with
different types of phospholipid. Sou et al. [58] have successfully prepared a curcumin lipid
formulation using 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC) and an anionic
amphiphile, L-glutamic acid, N-(3-carboxy-1-oxopropyl)-, 1,5-dihexadecyl ester (SA).
Intravenous administration of this formulation in rats showed no acute response in
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circulating blood cells and much of the curcumin accumulated in bone marrow and spleen
tissues. A recent pharmacokinetic study of solid lipid curcumin NPs in patients with
osteosarcoma reported up to 31.42–41.15 ng/ml of curcumin within 4 h of 2000–4000 mg
oral dose treatment [59]. More importantly, the patients did not experience any adverse
effects. In another study, solid lipid NPs with 134 nm and 84% encapsulation of curcumin
exhibited slow release of curcumin over a week [60]. This formulation resulted in high oral
bioavailability in plasma of male Wistar rats. Curcumin solid lipid NPs at a single oral dose
of 1, 12.5, 25 and 50 mg/kg pharmacokinetics in rats achieved a maximum concentration
(Cmax) of bioavailability in serum 1.00±0.01, 7.87±3.02, 8.00±1.87, and 14.29±0.15 µg/ml,
respectively, whereas free curcumin was only present at 0.292±0.06 µg/ml, even at a dose of
50 mg/kg. This enhancement in bioavailability is to the result of increased curcumin
absorption.
A comparative study revealed the uptake of liposome- and serum albumin-loaded curcumin
formations in normal spleen lymphocytes and EL4 lymphoma cells via fluid phase
pinocytosis and membrane fusion, respectively [61]. Curcumin-loaded liposomal
formulation was a better delivery vehicle and further significant absorption and fluorescence
levels in lymphoma cells compared with normal cells were observed. Li et al. [62] evaluated
the lipid curcumin ratio (10:1 wt./wt.) on various pancreatic carcinoma cell lines, including
ASPC-1, BxPC-3, Capan-1, Capan-2, HS766-T and MiapaCa2, and demonstrated an
inhibition concentration of IC50 at 2.0–37.8 µM, whereas IC90 was 6.75–94.5 µM, as
assessed by cytotoxicity. In a recent study, curcumin was successfully incorporated in egg-
phosphatidylcholine (EPC) liposomes at a 1:14 molar ratio (curcumin:liposome). A twofold
increase in concentration of curcumin was present in rat plasma with the lecithin curcumin
formulation compared with a curcumin and curcumin-lecithin mixture after administration
of a single oral dose of 100 mg curcumin/kg body weight [63]. Narayanan et al. [64]
provided an interesting insight into the use of curcumin and resveratrol in liposome to
evaluate their combined effects on: (i) cell growth, apoptosis and the cell cycle; and (ii) on
activated p-Akt, cyclin D1, mammalian target of rapamycin (m-TOR) and androgen receptor
(AR) proteins involved in tumor progression of PTEM-CaP8 prostate cancer cells. Overall,
this combined formulation significantly decreased prostatic adenocarcinoma in vivo (P
<0.001) and incidence. Transferrin-solid lipid NPs retained up to 83% of curcumin for 6
months and specifically targeted MCF-7 breast cancer cells four- and fivefold in 24- and 48-
h treatments, respectively [65]. Transferrin-mediated endocytosis was confirmed, which
promotes reactive oxygen species (ROS) and time-dependant apoptosis by transferrin-solid
lipid curcumin NPs. Curcumin structural features facilitated nanodisk NPs comprising a
disk-shaped lipid bilayer formation usually stabilized by an apolipoprotein scaffold [66].
The efficacy of anticancer properties of this lipid curcumin formulation in human
hepatocellular carcinoma (HepG2) was significant over that of free curcumin.
Curcumin encapsulated polymer NPs
Poly(lactic-co-glycolic acid) (PLGA) is a widespread choice in the production of a variety of
biomedical devices owing to its biodegradability and biocompatibility. In an effort to create
a safe carrier, several different types of PLGA NP for curcumin encapsulation have been
explored. A simple solid–oil–water solvent evaporation method has been used to prepare
curcumin-encapsulated PLGA NPs [67]. The particle size can be controlled by the surfactant
concentration and sonication time. Subsequently, our solvent evaporation method is
designed to regulate the curcumin-encapsulated PLGA NPs through a lower particle size,
enhanced intracellular uptake and antibody conjugation features [23]. The development of
surface-modified PLGA NPs with a thiolated chitosan was first studied by Grabovac and
Bernkop [68]. Surface functionalization of curcumin-loaded PLGA NPs by a
bis(sulfosuccinimidyl)suberate (BS3) facilitates conjugation of annexin A2 and results in an
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efficient target therapy of curcumin to annexin A2-positive MDA-MB-231 cancer cells [69].
Shahani and Panyam [70] designed a sustained and injectable microparticle formulation with
higher curcumin loading capacity (i.e. 38.1 mg/100 mg of particles; 76.2% encapsulation
efficiency) compared with many formulations. An improved glutathione-s-transferase (GST)
activity in liver was noticed with injectable microparticles and this observed phenomenon
was consistent over 4 weeks. GST activity represents a potent endogenous defense
mechanism against carcinogens. In vivo mice studies using this formulation resulted in a
tenfold increase in the concentration of curcumin blood, lungs and brain compared with
curcumin dissolved in PEG 400 formulation [71]. Tsai et al. [72] designed curcumin-loaded
PLGA and demonstrated the half-life of curcumin in the cerebral cortex and hippocampus to
be significantly increased from 2.32 to 19.9 and 7.56 to 16.7 min, respectively. Additionally,
retention time values of the cerebral cortex and the hippocampus were increased
approximately 2.0- and 1.8-fold, respectively. The curcumin plasma levels were slightly
higher with this nanoformulation.
Nanoformulations based on dextran sulfate-chitosan are considered to be biocompatible
materials that can be used for oral, intravenous and controlled delivery purposes. Another
study quantified the cellular uptake of curcumin encapsulated in dextran sulfate-chitosan
NPs using a spectrophotometric method in L929, MCF-7, PC3 and MG 63 cells [73].
Furthermore, a cytotoxicity assay and fluorescence-activated cell sorting (FACS) study
suggested that anticancer activity of this formulation is high in MCF-7 compared with other
cancer cells. A curcumin analog encapsulated in polycaprolactone (PCL) NPs
(approximately 650 nm) administered intravenously to male Wistar rats demonstrated higher
intracellular levels in liver cells, which suggests that this formulation can be used to target
the liver [74]. Co-encapsulation of curcumin and doxorubicin in polymer NPs enabled multi-
drug resistance cancer cells (K562 cells) to be treated more effectively [75]. Initial curcumin
release from NPs downregulated MDR1 and BCL-2 expression and inhibited the nuclear
efflux mechanism; the subsequent release of doxorubicin stimulated cancer cell death. A
patented technology described by synthesis of curcumin-encapsulated chitosan NPs proved
to be safe in mice and rat studies at a dose of 4 mg and 40 mg of formulations, respectively,
for 14 days [76].
Curcumin self-assemblies and nanogel
A few different methodologies have been developed for curcumin complexation or self-
assembly formation with β-cyclodextrin and their derivative(s). In addition, a few possible
host–guest complexations of β-cyclodextrin and curcumin have been reported recently [24].
This type of inclusion process offers suppression of curcumin degradation, stability,
dispersibility and bioavailability [13–17,77]. US patents were recently approved for
cyclodextrin–curcumin complexes to improve water solubility, stability and their effective
use in medical, pharmaceutical and nutraceutical applications [78,79].
A few complexes of diblock copolymer, modified starch and cyclodextrins have also been
successful in increasing the solubility of curcumin 1670–131 000 times [80–82]. Curcumin–
rubusoside (CUR–RUB) complexes with 8-nm particles efficiently increased curcumin
solubility from 61 µg/ml to 2.318 mg/ml depending upon the RUB range (1% to 10% (w/v)
used in the complexation [83]. This CUR–RUB complex demonstrated stability under
physiological conditions, did not form clusters or precipitation, and no degradation was
observed. It also showed anticancer efficacy against human colon, breast, and pancreatic
cancer cell lines. β-casein (B-CN) is an amphiphilic self-assembling protein that helps to
solubilize curcumin more efficiently in aqueous solution [84]. This micellar curcumin
solubility is 7.7 × 10−5 mol/l, whereas that of curcumin is only 2.99 × 10−8 mol/l. This
suggests at least a 2500-fold enhancement in the solubility of curcumin.
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A cyclodextrin–curcumin self-assembly has shown greater effects over curcumin in
inhibiting tumor necrosis factor (TNF)-induced expression of NF-kB regulated genes
(VEGF, MMP-9 and cyclin D1) and upregulation of death receptors (DR4 and DR5) in
KBM-5 cancer cells [85]. A similar pattern of encapsulation of curcumin into cyclodextrin
and poly(cyclodextrin) led to a self-assembly formation that promoted its anticancer
potential by downregulating pro-survival Bcl2 family genes, Bax and Bcl-xL, and induction
of apoptosis (cleaved poly[ADP-ribose]polymerase, [PARP]) [25]. Hydration of curcumin in
the presence of poly(ethylene)–cholesteryl ether (PEG–Chol) to produce uniform NPs (10
nm) showed an synergistic effect on myeloma (RPMI 8226, U266 and 5TGM1) cell lines
[86]. An exploratory study designed intracellular-labile amphiphilic surfactant-like curcumin
with short oligo(ethylene glycol) chains via β-thioester bonds that are easily labile in the
presence of glutathione and esterase [87]. This formulation achieved higher inhibition
potential in cancer cell lines as well as in athymic mice xenograft SKOV-3 tumors and
MDA-MB-468 tumors. A complex of liposome, PEG and polyethylene glycol was used to
encapsulate curcumin [88]. The complex exhibited 5- and 20-fold higher inhibitory effects
on HepG2, HT-29, HeLa, A549, CT26/cur-r and B16F10/cur-r adenocarcinoma cells. A 60–
90% inhibition of tumor growth was observed in mice bearing CT-26 or B16F10 cells with
this curcumin nanoformulation.
Crosslinked copolymer nanogels were synthesized through redox-free radical
polymerization of N-isopropylacrylamide, N-vinyl-2-pyrrolidone in the presence of PEG
monoacrylate [28]. The free network structures throughout the hydrogel NPs offer the
opportunity to load various types of lipophilic drug molecule. Bisht et al. [89] tested the
effects of hydrogel nanocurcumin formulation on pancreatic cancer cell lines.
Nanocurcumin efficiently blocked the activation of NF-κB, downregulated steady-state
transcripts of multiple pro-inflammatory cytokines and inhibited interleukin (IL)-6
synthesis. The parenteral administration of the hydrogel nanocurcumin formulation
significantly inhibited tumor growth in both subcutaneous and orthotopic settings in
xenograft models of human pancreatic cancer in athymic mice [90]. Furthermore, hydrogel
nanocurcumin and gemcitabine treatments promoted a tumor growth inhibition capacity, a
result that supports an additive therapeutic strategy. This new formulation has the potential
to overcome clinical translation of curcumin in cancer treatment as a result of its improved
systemic bioavailability as well as therapeutic efficacy. The nanocurcumin formulation has
achieved a dose-dependant anti-proliferation effect in embryonal tumor-derived lines DAOY
and D283Med, and the glioblastoma neurosphere lines HSR-GBM1 and JHH-GBM14 [91].
A series of curcumin-loaded dextran-modified hydrogel NPs were studied by Goncalves et
al. [92]. Another group described fabrication of curcumin-encapsulated chitosan-PVA silver
nanocomposite, poly(acrylamide)-poly(vinyl sulfonic acid) silver nanocomposite, and
poly(acrylamide)-carboxymethyl cellulose magnetic nanocomposites to improve the
therapeutic effects of curcumin [93]. Curcumin-loaded hydrogel NPs using PVP and
hydroxyl propyl methyl cellulose in the presence of pluronic® F68 have been formulated
using a solvent emulsion-evaporation technique [94]. The developed hydrogel NPs
(approximately 100 nm) have proven oral and cellular safety in a study using mice.
Novel curcumin nanoformulations
Kurien and Scofield pointed out that heat-stabilized curcumin in water increased the water
solubility of curcumin from 0.6 µg/ml to 7.4 µg/ml (an approximately 12-fold increase)
without altering its biological activity [95]. Curcumin-loaded monopolymer (ethylcellulose,
EC) and dipolymer (a blend of ethylcellulcose-methylcellulose, ECMC) nanoformulations
fabricated through a self-assembly process exhibited dose-dependant free radical scavenging
and cytotoxicity effects in MCF-7 and HepG2 cancer cells [96]. Through scanning electron
microscopy, these NPs have shown an improved adherence to stomach mucosa and
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sustained release of curcumin into the circulation. A combined glycerol monooleate and
pluronic F-127 polymer nanocarrier is also well suited to the delivery of curcumin to various
types of cancer cell (i.e. PANC-1, MiaPaCa-2, K-562, MCF-7, A549 and HCT-16) [97].
This formulation has shown significant anticancer properties at all concentrations (5–30
µM) compared with free curcumin. These improved effects are correlated with the inhibition
of phosphorylation and activation of the Akt pathway, which inactivates NF-κB and inhibits
the proliferation and induction of apoptosis. Silk fibroin NPs less than 100 nm entrap more
than 96% of curcumin molecules within their nanostructures, compared with all other silk
fibroin chitosan blend NPs [98]. Modified curcuminoid (i.e., 4-[3,5-bis(2-
chlorobenzylidene-4-oxo-piperidine-1-yl)-4-oxo-2-butenoic acid]; CLEFMA) was
successfully entrapped within a CD-liposome [99]. In nude rats bearing a H441xenograft, a
94% reduction in tumor volume was noticed after intravenous treatment with CLEFMA
liposomes (Figure 4). No apparent toxicity issues in liver, lung and kidney were observed
upon treatment, as confirmed by histopathological examination.
These curcumin NPs, formed by surfactant micelles of cetyltrimethylammonium bromide
(CTAB) into micelle rod shapes, facilitate the uptake of curcumin compared with the
traditional spherical micelle arrangement [100]. A similar approach of encapsulating
curcumin in silica magnetic NP reservoirs without altering the magnetization properties, has
been used for prototype material for targeted drug delivery [101]. A comparative
pharmacokinetic and bio-distribution study in mice administered curcumin encapsulated
poly(n-butylcyanoacrylate) NPs (5 mg/kg) and curcumin (10 mg/kg) via the tail vein [102].
The mean residence time and area of concentration of curcumin NPs were increased 14- and
2.53-fold, respectively, compared with that of curcumin solution. This increased distribution
was the result of receptor-mediated uptake.
Our group has recently developed a curcumin nanoformulation with multiple properties,
such as anticancer potential, hyperthermia and imaging [27]. The combining of therapeutic
and diagnostic (theranostic) properties into a single nanoplatform might result in a
significantly improved approach over conventional medicine. NPs comprising Eudragit®
S100 (a copolymer of methacrylic acid and methyl acrylate) and curcumin demonstrated no
acute, subacute or genotoxicity issues in a study of mice [103]. Furthermore, this
formulation was highly hemocompatible with human red blood cells. Theracurcumin
(curcumin NPs) was studied for the first time in six human volunteers at a single oral dose of
150 mg followed by a 210 mg dose after 2 weeks. No toxicities were found other than
diarrhea. The AUC was 2649 ± 350 and 3649 ± 430 ng/ml × h; and the t (1/2) was 9.7 ± 2.1
h 13.0 ± 3.3 h for 150 mg and 210 mg doses, respectively [104].
Prospects and conclusions
Several types of NP have been found to be suitable for the encapsulation or loading of
curcumin to improve its effects in cancer therapeutics. The characteristics of these curcumin
nanoformulations can be tailored according to the specific requirement for inducing cellular
death by various mechanisms. Overall, our understanding from the available literature is that
the use of curcumin nanoformulations in chemotherapy for cancer treatment is a facile
modality that improves existing curcumin therapies by targeting tumors and by reducing the
dose required. Safe toxicological profiles of the various curcumin nanoformulations and
their efficacy in the cell-line models highlight their potential for evaluation in in vivo
models. Human trials need to be conducted to establish their effectiveness in clinical
applications as an improved therapeutic modality for cancer treatment.
Although curcumin NPs have many advantages for chemotherapy, the main obstacle is lack
of tissue specificity. Thus, in addition to delivering the drug to the cancer cells, it also
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spreads to surrounding healthy tissues. Therefore, future studies that combine curcumin
delivery with other first-line anticancer chemotherapeutic agents or imaging-, contrast-,
antibody- or peptide-targeted delivery are needed to achieve better-targeted therapeutic
modalities. Additionally, studies are needed that evaluate the efficacy and toxicity of
curcumin NP formulations in both small and large cohorts, as well as in patients with cancer
in phase I/II clinical trials. These studies would compare the anticancer efficiency of
curcumin NP formulations and free curcumin and reveal whether curcumin NP formulations
can be developed as a useful modality for cancer treatment.
Various curcumin nanoformulations developed at the laboratory scale are based on dispersed
or precipitation processes. It is important to regulate the size of curcumin NPs to between 10
nm and 200 nm for drug delivery applications. Overall, these developed processes must be
simple, efficient, continuous and suitable for large-scale convertible production that is
acceptable by regulatory authorities. In addition, a process with flexible amounts of
curcumin loading or encapsulation is also desirable. Adopting commercialized approaches
for curcumin nanoformulations similar to nanocrystal, nanomorph, nanoedge, nanopure,
crititech and nanocochleate technology would aid immediate implementation in the drug
market. In conclusion, the overall experimental evidence suggests that curcumin-based NP
formulations hold great promise in cancer therapeutics as anticancer chemotherapeutic
agents that target and sustain curcumin delivery in tumors.
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Types of curcumin nanoformulation used in cancer therapeutics. (a) Various types of
curcumin nanoformulation developed during the past 10 years. (b) Increased use of
curcumin nanoformulations during the past decade. Data were collected from journals
published by Elsevier, Wiley Interscience, American Chemical Society, Springer, BMC
Central and PubMed. * indicates data collected from Jan 2011 to July 2011. (c)
Chemotherapeutic effects in PC-3 cancer cells of poly(lactic-co-glycolic acid) (PLGA)
nanoparticles (nanoCUR) over free curcumin (CUR) through the formation of vacuoles
involving the entire cell structure, as observed under a transmission electron microscope.
Abbreviation: N, nucleus. Black arrows indicate vacuoles.
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Size-dependant absorption characteristics of drug crystals and curcumin crystal formation.
(a) Large drug crystals have poor absorption properties, whereas smaller particles (micro–
nanometer) result in rapid dissolution and bioavailability. (b) Curcumin drug particle
formation and conversion into precipitation in a bottom-up approach in an alcohol and water
mixture with time. Reprinted, with permission, from [31].
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Improved therapeutic effects of curcumin by curcumin conjugate (PCurc8) formulation in
cancer cells. (a) Cytotoxicity effect of PCurc 8 formulation in SKOV-3, OVCAR-3 and
MCF-7 cancer cell lines after 72-h incubation followed by 24-h incubation in free medium.
(b) Intracellular localization of curcumin conjugate observed by confocal microscopy.
SKOV-3 ovarian cancer cells incubated with PCurc 8 at 25 µg/ml for 2 h (i–iii) and 24 h
(iv–vi). PCurc 8 channel (green, left column) and the LysoTracker® channel (red, middle
column), and overlapped channels (right column). (vi) also indicates the overlap of the
nuclear dye channel with a blue color. (c) Immunoblotting with anti-cyclin D1, CDK4,
CDK6 and procaspase-3 antibodies after treating cells with 10, 20 and 40 µg/ml of PCurc 8.
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Downregulation of CDK4 and CDK6 indicates that the SKOV-3 cells were hindered at the
G0/G1 or G1 phases before going into S phase. Reprinted, with permission, from [47].
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Schematic representation of 4-[3,5-bis(2-chlorobenzylidene-4-oxo-piperidine-1-yl)-4-oxo-2-
butenoic acid] (CLEFMA) liposomes obtained by a drug-in CD-in liposome method,
detailing tumor volume control with liposomal CLEFMA treatment. Insets show
representative pictures of excised tumors upon necropsy. The dashed lines are the trend lines
of the plotted data. The data are presented as the mean ± SEM of results from experiments
on n = 4 (treatment) and n = 3 (control) rats.Reprinted, with permission, from [99].
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Table 1
A comprehensive list of commercially available curcumin NP formulations
Curcumin nanoformulation Composition Company name and website
Liposomal curcumin Curcumin, phospholipids from lecithin, natural




NanoBioSphere™ complex (solid lipid
nanocurcumin)
Vitamin E (d,l-alpha tocopherol, sunflower oil,
phospholipids, saffloweroil, ethanol, medium-
chain triglycerides, glycerin, glyceryl stearate,
ascorbyl palmitate with curcumin C3 complex,
solid triglyceride and phosphatidylcholine
Life Enhancement Products, Inc., USA;
http://www.life-enhancement.com
Curcumin C3 complex® vegetarian
capsules
Curcumin C3 complex, curcuminods and black
pepper extract (Piper nigrum; from fruit)
BestVite, Inc., USA; http://www.bestvite.com
Nanocurcumin (N-curcusorb) Curcumin in nanosized particles Konark Herbals & Health Care, India;
http://www.curcuminindia.com
CurcuPlus D Ultra™ Curcumin (Longvida®), vitamin D3, ascorbyl
palmitate, microcrystalline cellulose, soy lecithin,
stearic acid, maltodextrin and silicon dioxide
Advanced Orthomolecular Research, Inc.,
Canada; http://www.aor.ca/
Nanocurcumin (in the scale-up process) Liposomal curcumin formulation; nanocurcumin
formulation; PLGA-curcumin formulation





Curcumin particles, vegetable-derived stearic acid
dextrin, hydroxypropyl methylcellulose
(vegetarian capsule), soy lecithin, ascorbyl
palmitate and silicon dioxide




A special curcumin compound Lee Silsby Compounding Pharmacy, USA;
http://www.leesilsby.com
Nano curcumin/nano curcuma Nanocurcumin solution (colloid) products Nano Tech Miso-N, Korea;
http://www.miso-n.co.kr
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